Core Insights - Profusa, Inc. is set to present findings from its pilot clinical study on tissue oxygen monitoring in peripheral artery disease (PAD) patients at the Leipzig Interventional Course (LINC) 2026, scheduled for January 27-30, 2026 [1] - The company's Lumee technology allows for continuous, real-time measurement of tissue oxygen, aimed for both clinical and home use, with positive feedback received from the U.S.-based clinical study [2] - Profusa is a digital health company focused on developing tissue-integrated sensors that provide actionable, medical-grade data for personal and medical use, emphasizing affordability and long-lasting biosensors [3] Company Overview - Profusa is based in Berkeley, California, and is led by a team of experienced management and a world-class board of directors [3] - The company aims to deliver a personalized biochemical signature that clinicians can trust, utilizing its intelligent data platform [3] - The trademarks "LUMEE," "PROFUSA," and the PROFUSA logo are registered in multiple regions including the United States, Canada, and the European Union [4]

Core Insights - Profusa, Inc. is set to present a Late Breaking Clinical Trial Update on its Lumee™ Oxygen tissue monitoring platform at the Paris Vascular Insights (PVI) 2025 conference, highlighting its innovative technology for continuous monitoring of tissue oxygen in patients with peripheral artery disease [1][2] - The Lumee technology allows for real-time measurement of tissue oxygen levels directly within the body, representing a significant advancement in biochemistry monitoring for both clinical and home use [2][3] - Profusa aims to provide personalized biochemical data through its long-lasting, injectable biosensors, which are designed to deliver actionable medical-grade information for both personal and medical applications [3] Presentation Details - The presentation titled "Monitoring Tissue Oxygen Dynamics with a Novel Implantable Hydrogel Sensor in Patients with Peripheral Arterial Disease (PAD)" will be delivered by Dr. Peter Schneider on December 13, 2025, at 1pm CET [2] - The event will take place at the Carrousel du Louvre in Paris, France, showcasing the latest innovations in vascular and endovascular surgery [2] Company Overview - Profusa is based in Berkeley, California, and is recognized for its pioneering work in developing tissue-integrated sensors that continuously transmit reliable biochemical data [3] - The company is led by a team of experienced professionals and aims to create a new generation of affordable biosensors that enhance patient care through personalized data [3]